You are here: Industry Insights > Celgene

News List

Celgene gets fast FDA review of Revlimid combo in lymphoma pharmaphorum
February 28, 2019
Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan.
BMS can breathe easier now: Celgene’s Revlimid has escaped a big patent challenge fiercepharma
February 24, 2019
When Bristol-Myers Squibb picked up Celgene in one of biopharma’s biggest deals ever last month, investors tagged one big risk: Celgene’s megablockbuster Revlimid faced patent challenges that could take a big bite out of sales.
Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene firstwordpharma
February 23, 2019
The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12, 2019 at 10:00 a.m. Eastern Time.
Celgene continues dealmaking via agreements with Kyn Therapeutics, Obsidian Therapeutics firstwordpharma
January 21, 2019
Under the first agreement, Celgene will make an upfront cash payment of $80 million to Kyn, whilst also making an equity investment in the company. In return, Celgene will gain exclusive options to globally license Kyn's kynurenine-degrading enzyme and ar
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies pharmafocusasia
January 21, 2019
Kyn Therapeutics, a clinical-stage biotechnology company advancing research into new immunometabolic therapies for treating cancer...
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies pharmafocusasia
January 21, 2019
Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced a strategic collaboration with ....
Celgene invests in Antengene; Otsuka’s new digital-pill pact; MabSpace-HJB merger fiercepharma
January 10, 2019
China's Antengene has raised $120 million in its second financing round, with a contribution from partner Celgene. Otsuka has signed Click Therapeutics in a digital medicine deal potentially worth $305 million. Chinese firms MabSpace and HJB have merged t
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal fiercepharma
January 08, 2019
It’s not only Celgene investors who are set for a big payoff with this week’s $74 billion sale to Bristol-Myers Squibb. Thanks to brand-new severance agreements inked days ahead of the deal announcement, its top executives could reap hefty gains, too.
Bristol-Myers Squibb to buy Celgene pharmatimes
January 08, 2019
Bristol-Myers Squibb has announced that it is to acquire Celgene, in order to “create a premier innovative biopharma company” and expand its cancer and immunotherapy offering.
Celgene invests in Chinese biotech Antengene again fiercebiotech
January 04, 2019
China’s Antengene has raised another $120 million in a second-round financing, with partner Celgene contributing to the tally....

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page